<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940916-2-00059</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Prospective Grant of Co-Exclusive License: Second Generation Monoclonal Antibodies Having Binding Specificity to TAG&hyph;72 and Human Carcinomas and Methods for Employing the Same </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, Public Health Services, DHHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of limited field of use co-exclusive worldwide licenses to practice the invention embodied in U.S. Patent Applications Number 07/073,685 filed on July 15, 1987 and Number 07/547,336 filed on July 20, 1990, entitled ``Second Generation Monoclonal Antibodies Having Binding Specificity to TAG&hyph;72 and Human Carcinomas and Methods for Employing the Same'', to Centocor, Inc., having a place of business in Malvern, PA, and to Miles, Inc., having a place of business in Tarrytown, NY. The patent rights in this invention have been assigned to the United States of America.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The antibodies covered in this patent application have a higher binding affinity and specificity to a tumor associated glycoprotein (designated TAG&hyph;72) than previous monoclonal antibodies available against TAG&hyph;72. The current antibodies also exhibit binding specificity to more human carcinomas than the previous monoclonals, while maintaining essentially no specificity to normal adult human tissues.  <!-- PJG 0012 frnewline --> The prospective co-exclusive licenses will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive licenses may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the licenses would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.  <!-- PJG 0012 frnewline --> The field of use would be limited to  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vitro  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> non-radioimmunodiagnostic assays utilizing TAG&hyph;72 antibody. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Dr. Judith Plesset, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852&hyph;3804. Telephone: (301) 496&hyph;7735, ext 247; Facsimile: (301) 402&hyph;0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent application. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before November 15, 1994 will be considered.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: August 31, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ADDRESS> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Barbara M. McGarey, J.D.,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Director, Office of Technology Transfer.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;22995 Filed 9&hyph;15&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            